A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler compared with usual maintenance therapy in subjects with Asthma

Trial Profile

A 12-month, open label, randomised, effectiveness study to evaluate fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler compared with usual maintenance therapy in subjects with Asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Vilanterol/fluticasone furoate (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms SLS
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 11 Sep 2017 Results published in a GlaxoSmithKline Media Release.
    • 11 Sep 2017 According to a GlaxoSmithKline media relaes, Ashley Woodcock from University of Manchester is the lead investigator.
    • 11 Sep 2017 Primary endpoint (The percentage of subjects who have an ACT total score of 20 at Week 24 (6th month) assessment.) has been met as per the results published in the Lancet
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top